Do analysts rate ADXS or RFAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, ADXS or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Ayala Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ayala Pharmaceuticals $3.24M 11.05 -$48.07M -$5.02 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Is ADXS or RFAI more profitable?

Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A RF Acquisition Corp II N/A N/A N/A

Do analysts rate NMRA or ADXS?

Neumora Therapeutics currently has a consensus price target of $6.57, indicating a potential upside of 849.90%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NMRA or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -242.28% -131.32% Ayala Pharmaceuticals N/A N/A N/A

Is UNCY or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% Ayala Pharmaceuticals N/A N/A N/A

Do analysts recommend ADXS or LENZ?

LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 605.88%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts rate ADXS or VTVT?

vTv Therapeutics has a consensus target price of $55.83, indicating a potential upside of 78.38%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Is ADXS or VTVT more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat vTv Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A vTv Therapeutics N/A -6.27% -5.06%

Ayala Pharmaceuticals (ADXS) Competitors

$0.60 0.00 (0.00%)

As of 09/18/2026

Compare

ADXS vs. RFAI, NMRA, UNCY, LENZ, and VTVT

Should you buy Ayala Pharmaceuticals stock or one of its competitors? Ayala Pharmaceuticals's main competitors and comparable companies include RF Acquisition Corp II (RFAI), Neumora Therapeutics (NMRA), Unicycive Therapeutics (UNCY), LENZ Therapeutics (LENZ), and vTv Therapeutics (VTVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ayala Pharmaceuticals compare to RF Acquisition Corp II?

Ayala Pharmaceuticals (NASDAQ:ADXS) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
RF Acquisition Corp II	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

RF Acquisition Corp II has lower revenue, but higher earnings than Ayala Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

In the previous week, RF Acquisition Corp II had 10 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 10 mentions for RF Acquisition Corp II and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled RF Acquisition Corp II'saverage media sentiment score.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
RF Acquisition Corp II	Neutral

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Summary

Ayala Pharmaceuticals and RF Acquisition Corp II tied by winning 3 of the 6 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Neumora Therapeutics currently has a consensus price target of $6.57, indicating a potential upside of 849.90%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals' return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Ayala Pharmaceuticals	N/A	N/A	N/A

In the previous week, Neumora Therapeutics had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Neumora Therapeutics and 0 mentions for Ayala Pharmaceuticals. Neumora Therapeutics' average media sentiment score of 0.45 beat Ayala Pharmaceuticals' score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Neutral
Ayala Pharmaceuticals	Neutral

Ayala Pharmaceuticals has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Neumora Therapeutics has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Summary

Neumora Therapeutics beats Ayala Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Unicycive Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 293.08%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Unicycive Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Unicycive Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	195.36	-$26.56M	-$1.75	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Ayala Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Ayala Pharmaceuticals	N/A	N/A	N/A

In the previous week, Unicycive Therapeutics had 13 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 13 mentions for Unicycive Therapeutics and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Unicycive Therapeutics' score of -0.01 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Ayala Pharmaceuticals	Neutral

Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Summary

Unicycive Therapeutics beats Ayala Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to LENZ Therapeutics?

Ayala Pharmaceuticals (NASDAQ:ADXS) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 605.88%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Ayala Pharmaceuticals has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
LENZ Therapeutics	$19.09M	6.72	-$82.13M	-$4.09	N/A

Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, LENZ Therapeutics had 3 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Ayala Pharmaceuticals. LENZ Therapeutics' average media sentiment score of 0.34 beat Ayala Pharmaceuticals' score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
LENZ Therapeutics	Neutral

Ayala Pharmaceuticals has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Ayala Pharmaceuticals' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Summary

LENZ Therapeutics beats Ayala Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Ayala Pharmaceuticals (NASDAQ:ADXS) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Ayala Pharmaceuticals' return on equity of 0.00% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
vTv Therapeutics	N/A	-6.27%	-5.06%

Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

vTv Therapeutics has a consensus target price of $55.83, indicating a potential upside of 78.38%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

vTv Therapeutics has lower revenue, but higher earnings than Ayala Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
vTv Therapeutics	$1.02M	120.90	-$26.97M	-$1.06	N/A

In the previous week, vTv Therapeutics had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for vTv Therapeutics and 0 mentions for Ayala Pharmaceuticals. vTv Therapeutics' average media sentiment score of 0.15 beat Ayala Pharmaceuticals' score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
vTv Therapeutics	Neutral

Summary

vTv Therapeutics beats Ayala Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXS vs. The Competition

Export

Metric	Ayala Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.79M	$12.50B	$7.25B	$12.97B
Dividend Yield	N/A	2.64%	2.53%	12.80%
P/E Ratio	-0.08	789.79	274.71	25.77
Price / Sales	11.05	945.12	696.46	109.69
Price / Cash	N/A	15.08	28.04	34.72
Price / Book	-0.29	10.57	10.56	6.36
Net Income	-$48.07M	$2.82B	$3.49B	$358.17M
7 Day Performance	N/A	0.46%	0.80%	1.60%
1 Month Performance	N/A	-1.16%	-2.80%	-2.97%
1 Year Performance	302.37%	4.23%	16.68%	5.63%

Ayala Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
RFAI RF Acquisition Corp II	0.9172 of 5 stars	$39.81 -3.2%	N/A	+253.2%	$139.74M	N/A	N/A	2
NMRA Neumora Therapeutics	2.2478 of 5 stars	$0.73 -2.7%	$6.57 +800.2%	-60.7%	$137.16M	N/A	N/A	63	High Trading Volume
UNCY Unicycive Therapeutics	3.0971 of 5 stars	$4.80 +0.6%	$18.75 +290.6%	+20.5%	$133.70M	N/A	N/A	22
LENZ LENZ Therapeutics	2.7434 of 5 stars	$4.07 -1.5%	$28.80 +607.6%	-90.3%	$127.88M	$21.48M	N/A	152

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXS) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. RFAI, NMRA, UNCY, LENZ, and VTVT

How does Ayala Pharmaceuticals compare to RF Acquisition Corp II?

Summary

How does Ayala Pharmaceuticals compare to Neumora Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to LENZ Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. RFAI, NMRA, UNCY, LENZ, and VTVT

How does Ayala Pharmaceuticals compare to RF Acquisition Corp II?

Is ADXS or RFAI more profitable?

Do analysts rate ADXS or RFAI?

Do institutionals & insiders have more ownership in ADXS or RFAI?

Which has higher valuation & earnings, ADXS or RFAI?

Does the media prefer ADXS or RFAI?

Which has more volatility and risk, ADXS or RFAI?

Summary

How does Ayala Pharmaceuticals compare to Neumora Therapeutics?

Do analysts rate NMRA or ADXS?

Is NMRA or ADXS more profitable?

Does the media prefer NMRA or ADXS?

Which has preferable earnings and valuation, NMRA or ADXS?

Do institutionals and insiders have more ownership in NMRA or ADXS?

Which has more risk & volatility, NMRA or ADXS?

Summary

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Do analysts rate UNCY or ADXS?

Do insiders & institutionals have more ownership in UNCY or ADXS?

Which has better earnings & valuation, UNCY or ADXS?

Is UNCY or ADXS more profitable?

Does the media favor UNCY or ADXS?

Which has more volatility and risk, UNCY or ADXS?

Summary

How does Ayala Pharmaceuticals compare to LENZ Therapeutics?

Do analysts recommend ADXS or LENZ?

Which has higher valuation & earnings, ADXS or LENZ?

Which has more risk & volatility, ADXS or LENZ?

Do insiders and institutionals have more ownership in ADXS or LENZ?

Does the media refer more to ADXS or LENZ?

Is ADXS or LENZ more profitable?

Summary

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Is ADXS or VTVT more profitable?

Which has more risk and volatility, ADXS or VTVT?

Do institutionals & insiders have more ownership in ADXS or VTVT?

Do analysts rate ADXS or VTVT?

Which has stronger earnings and valuation, ADXS or VTVT?

Does the media refer more to ADXS or VTVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools